Stoke Therapeutics
STOK
Stoke Therapeutics (STOK) news
Recent news
Stoke Therapeutics - May offer up to $200 mln in common stock - SEC filing
AInvest Wire · Aug 3, 2026Stoke Therapeutics Q2 EPS USD -0.93
Stoke Therapeutics (NASDAQ: STOK) reported its second-quarter 2026 earnings on August 12, 2025, with an earnings per share (EPS) of -$0.40, which exceeded the consensus estimate of -$0.46 by $0.06. The company’s quarterly revenue was $13.82 million, below the estimated revenue of $31.51 million.…
AInvest Wire · Aug 3, 2026Stoke Therapeutics - Phase 3 data readout anticipated in Q3 2027, to complete NDA submission in H2 2027
AInvest Wire · Jun 30, 2026Stoke Therapeutics - plans to initiate rolling U.S. NDA submission to FDA in Q1 2027
AInvest Wire · Jun 30, 2026Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.